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Spleen is known to contain multiple dendritic and myeloid cell subsets, distinguishable 
on the basis of phenotype, function and anatomical location. As a result of recent 
intensive flow cytometric analyses, splenic dendritic cell (DC) subsets are now better 
characterized than other myeloid subsets. In order to identify and fully characterize a 
novel splenic subset termed “L-DC” in relation to other myeloid cells, it was necessary to 
investigate myeloid subsets in more detail. In terms of cell surface phenotype, L-DC were 
initially characterized as a CD11bhiCD11cloMHCII−Ly6C−Ly6G− subset in murine spleen. 
Their expression of CD43, lack of MHCII, and a low level of CD11c was shown to best 
differentiate L-DC by phenotype from conventional DC subsets. A complete analysis 
of all subsets in spleen led to the classification of CD11bhiCD11cloMHCII−Ly6CloLy6G− 
cells as monocytes expressing CX3CR1, CD43 and CD115. Siglec-F expression was 
used to identify a specific eosinophil population, distinguishable from both Ly6Clo and 
Ly6Chi monocytes, and other DC subsets. L-DC were characterized as a clear subset 
of CD11bhiCD11cloMHCII−Ly6C−Ly6G− cells, which are CD43+, Siglec-F− and CD115−. 
Changes in the prevalence of L-DC compared to other subsets in spleens of mutant 
mice confirmed the phenotypic distinction between L-DC, cDC and monocyte subsets. 
L-DC development in vivo was shown to occur independently of the BATF3 transcrip-
tion factor that regulates cDC development, and also independently of the FLT3L and 
GM-CSF growth factors which drive cDC and monocyte development, so distinguishing 
L-DC from these commonly defined cell types.
Keywords: dendritic cells, monocytes, spleen, myeloid cells
inTrODUcTiOn
Characterization of dendritic cell (DC) subsets in spleen has progressed rapidly in terms of phenotype 
and function; however, other splenic myeloid subsets are less clearly defined. The term “myeloid” 
has been used as an umbrella term describing DC, granulocytes, and macrophages/monocytes, 
which descend from a common myeloid progenitor (CMP) in bone marrow (1). Granulocytes com-
prise neutrophils, eosinophils, basophils, and mast cells (2), while monocytes have been classified 
into distinct resident and inflammatory populations, in line with monocyte subsets described in 
peripheral blood (3). Recent definition of a common dendritic progenitor (CDP) now separates the 
development of conventional (c) and plasmacytoid (p) DC from other myeloid cell types (4, 5). The 
current classification of splenic myeloid subsets is based on cell surface phenotype, although full 
phenotypic profiles are not yet available. To date, studies focusing on specific subsets do not compare 
one subset against another to ensure pure populations and do not achieve a comprehensive picture 
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of the relationship between subsets. Accurate identification of 
splenic myeloid cell types is essential for distinguishing specific 
subsets and their function, and for making studies in the field 
comparable.
Monocytes develop in bone marrow from CMP and trav-
erse into blood as mature cells (1). Resident monocytes were 
described as having a longer half-life in blood than inflammatory 
monocytes (6) and were originally thought to act as precursors 
of tissue resident macrophages in the steady-state, hence their 
name “resident” monocytes (7). They were identified further as 
CC-chemokine receptor 2 (CCR2)− and CX3-chemokine recep-
tor 1 (CX3CR1)hiLy6CloLy6G− cells, which play an important role 
in the detection of vascular integrity (3, 8). Inflammatory mono-
cytes were described as distinct as CCR2+CX3CR1loLy6ChiLy6G− 
cells (3, 7, 9–11). Several studies have now highlighted how 
tissue-specific macrophages including microglial cells, alveolar 
macrophages, Langerhans cells and splenic macrophages have a 
yolk sac-derived origin rather than a bone marrow origin (12–15).
Most studies on monocytes have involved blood as a source 
of cells, but more recently the relationship between splenic 
monocytes and their blood counterpart has been considered. 
The studies of Swirski and colleagues demonstrated that splenic 
monocytes resemble their blood counterpart on the basis of 
phenotype, morphology and gene expression (16). Spleen was 
identified as a reservoir for monocytes, where Ly6Chi inflamma-
tory monocytes were efficiently deployed to sites of inflammation 
during cardiac arrest. Monocytes in blood and spleen are now 
identified as cells with a CD11bhiCD11c−/lo phenotype, with 
further distinction as Ly6Chi and Ly6Clo cells resembling inflam-
matory and residential monocytes, respectively (17). Neutrophils 
have not been extensively characterized in spleen and were previ-
ously delineated on the basis of phenotype as a blood equivalent 
CD11b+Ly6C+Ly6G+ subset (18). Similarly, eosinophils have 
been described in blood as CD11b+Siglec-F+CCR3+F4/80+ cells 
and in spleen as Ly6CintLy6G−SSChiSiglec-F+ cells (17, 19).
The lineage of DC is equally diverse with multiple sub-
sets defined in mice and humans (20, 21). All subsets are 
capable of antigen uptake, processing and presentation for 
T cell activation. Conventional DC are predominant in 
spleen, comprising CD8− and CD8+ populations, pheno-
typically distinct as CD11chiCD11b+CD8α−MHCII+ and 
CD11chiCD11b−CD8α+MHCII+ cells, respectively (22). These 
two dominant DC subsets are distinct in function, cytokine 
production and ability to cross-present antigen (23). Spleen also 
contains a smaller population of pDC existing as a plasmacy-
toid preDC (p-preDC) in the steady-state. These are, however, 
long-lived, circulating cells, which produce high levels of Type 
I interferon important in anti-viral immunity (24). Spleen also 
contains a variable population of poorly defined “myeloid DC.” 
As an example, under inflammatory conditions, circulating 
CD115+Ly6ChiCCR2+ monocytes in blood may be recruited into 
spleen where they differentiate to become “monocyte-derived 
(mo)-DC” (25–27). Different subsets of mo-DC can subsequently 
be observed in different disease states.
Novel dendritic-like cells termed L-DC, were recently 
discovered in murine and human spleen on the basis of their 
resemblance with dendritic-like cells produced in vitro in splenic 
long-term cultures (LTC-DC) (28–30), or in co-cultures of bone 
marrow precursors over selected splenic stroma (31, 32). L-DC 
have a distinct CD11bhiCD11cloMHCII−CD8− phenotype and 
dendritic-like appearance (33). Splenic stroma maintains con-
tinuous but restricted in vitro development of only this cell type, 
without addition of cytokines like GM-CSF, M-CSF, or Flt3L 
used by others to induce DC development in  vitro from bone 
marrow precursors (34). An in vivo equivalent L-DC subset has 
been partially characterized in spleens of mice and human (35, 
36). While L-DC resemble myeloid DC on the basis of CD11c 
and CD11b expression, lack of MHCII expression has raised 
criticism that L-DC may more resemble splenic monocytes/
macrophages than DC. Low expression of CD11c on L-DC is, 
however, consistent with some myeloid DC and pDC described 
as CD11clo cells (37–39).
Analysis of cell surface phenotype using specific antibodies 
and flow cytometry is widely accepted as a means to identify 
and distinguish ex vivo cell subsets. A staining protocol and 
gating strategy were therefore developed here to more accurately 
delineate and identify DC, monocytes, and other myeloid subsets 
in spleen. This study now identifies the L-DC subset in vivo as 
distinct from monocytes, granulocytes and cDC. The develop-
ment of L-DC has also been investigated in relation to cDC 
and myeloid subsets in the spleens of Batf-3−/−, GM-CSF−/−, and 
Flt3L−/− mutant mice. The GM-CSF and FLT3 ligand (FLT3L) 
growth factors are known to be important in the differentiation 
of dendritic and other myeloid cells (34), and the BATF3 tran-
scription factor was recently described as essential for CD8+ cDC 
development (40, 41).
MaTerials anD MeThODs
animals
C57BL/6J mice were bred at the John Curtin School of 
Medical Research (JCSMR: Canberra, ACT, Australia) 
under specific pathogen-free conditions. B6.129P(Cg)-
PtprcaCx3Cr1tm1LittLittJ(Cx3Cr1-GFP) mice were purchased from 
the Walter and Eliza Hall Institute (Parkville, VIC, Australia). 
C57BL/6-Flt3Ltm1lmx (Flt3L−/−) mice (Taconic Farms Inc., NY, 
USA) were purchased from the Biomedical Research Facility, 
University of Western Australia (Perth, WA, Australia). C57BL/6-
Csf2tm1Ard (GM-CSF−/−) mice were obtained from the Ludwig 
Institute for Cancer Research (Melbourne, VIC, Australia). 
C57BL/6-129S-Batftm1.1Kmm (Batf-3−/−) mice were provided 
through the courtesy of Ian Cockburn (JCSMR). Mice were 
housed and handled according to the guidelines of the Animal 
Experimentation Ethics Committee at the Australian National 
University (Canberra, ACT, Australia).
cell Fractionation
Dendritic and myeloid cells were enriched from dissociated 
whole spleen via negative depletion of T, B, and red blood 
cells using magnetic bead separation and MACS® technology 
(Miltenyi Biotec: Auburn, CA, USA). Depletion was performed 
by exposing cells to specific antibody, i.e., 0.2 μg biotinylated anti-
Thy1.2, anti-CD19, and anti-Ter119 antibody/108 cells in 1 mL of 
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MACS-labeling buffer (2 mM EDTA/0.5% BSA in PBS) on ice for 
25 min. Cells were then washed twice with MACS-labeling buffer, 
resuspended in buffer (108 cells/mL) followed by the addition of 
20 μL of anti-biotin microbeads/108 cells (Miltenyi), with incuba-
tion for 25 min on ice. The washing step was repeated, and cells 
resuspended in MACS-labeling buffer. T, B, and red blood cells 
were depleted by running cells through LS columns (Miltenyi) in 
a SuperMACS II Separation Unit (Miltenyi), washing thrice with 
3 mL of buffer and collection of unbound cells as flow-through.
antibody staining
Antibody staining followed by flow cytometry was performed 
to analyze cell surface marker expression as described previ-
ously (32). Non-specific antibody binding via Fc receptors was 
blocked by incubating cells (≤ 106) with anti-CD16/32 (FcBlock) 
(Biolegend: San Diego, CA, USA) at 5 μg/mL. Biotin- or fluoro-
chrome-conjugated antibodies specific for CD11c (N418), CD11b 
(M1/70), CD8 (53-6.7), CD19 (1D3), CD43 (IBII), Thy1.2 (30-
H12), Ter119 (Ter-119), F4/80 (CI:A3-1), IAb (25-9-17), Siglec-F 
(E50-2440), Ly6C (HK1.4), and Ly6G (1A8) were purchased from 
Biolegend. Antibody specific for CD115 (AFS98) was purchased 
from eBioscience (Parkville, VIC, Australia). Propidium iodide 
(PI, 1 μg/mL) was added prior to flow cytometry for discrimi-
nation of live and dead cells. Flow cytometry was performed 
immediately on a BD LSRII flow cytometer (Becton Dickinson: 
Franklin Lakes, NJ, USA). Data collected included forward scat-
ter (FSC), side scatter (SSC), and multiple fluorescence channels 
detecting fluorescein isothiocyanate (FITC), phycoerythrin (PE), 
PI, pacific blue (PB), Alexa Fluor-700, PE-indocyanine-7 (Cy7), 
allo-phycocyanin (APC), and APC-Cy7. BD FACSDiva Software 
(Becton Dickinson) was used to acquire data. Analysis of data 
involved post-acquisition gating using FlowJo software (Tree 
Star: Ashland, OR, USA). Analyses shown in Figures 1–4 were 
repeated at least thrice, but only representative data are shown. 
Replicates are shown for all other experiments.
cell sorting
Cell populations were isolated by sorting following flow cytom-
etry with fluorochrome-conjugated antibodies. Cells were pre-
pared as described above and all incubation and washing steps 
performed in 1% fetal calf serum in Dulbecco’s Modified Eagle 
Medium (DMEM). After a final wash prior to sorting, cells were 
filtered through a 70-μm nylon cell strainer (Becton Dickinson) 
for removal of cell clumps. Cell sorting was performed using a 
FACSAria cell sorter (Becton Dickinson). Sorted populations 
were collected in complete medium (10% fetal calf serum in 
DMEM) as described previously (32).
May-grünwald-giemsa staining
Cell staining with Giemsa was employed to morphologically dif-
ferentiate cells within sorted populations. Sorted cells (103–106) 
were pelleted on to a glass slide using a cytospin centrifuge. Cells 
were fixed in methanol, then stained in a two-step procedure with 
CliniPure staining solution 1 (0.25% Eosin YO/Soresen buffer, 
pH 6.8) followed by staining solution 2 (0.25% methylene blue 
polychrone/Soresen buffer, pH 6.8) (HD Scientific: Sydney, NSW, 
Australia) for 5 s at each step. Excess solution was rinsed off and 
slides dried before mounting. Non-aqueous Depex mounting 
agent (Fluka Analytical: Buchs, Switzerland) was used to prevent 
leaching of dye from stained cells. Photographs were taken with 
a LEICA DFC digital camera connected to a LEICA brightfield 
inverted microscope (LEICA Microsystems: Wetzlar, Germany).
statistical analysis
Data have been presented as mean ± SE for sample size n. For 
sample size n ≤ 5, the Wilcoxon Rank-Sum test was used to test 
significance (p ≤  0.05). Where a normal distribution could be 
assumed (n > 5), Students’ t-test was used to determine signifi-
cance (p ≤ 0.05).
resUlTs
identification of Myeloid subsets in spleen
In blood, both the described populations of Ly6Chi inflammatory 
and Ly6Clo-resident monocytes do not express Ly6G (3). Ly6Chi 
monocytes are distinct from neutrophils which express Ly6G 
as well as Ly6C. In order to identify myeloid cells in spleen, 
CD11bhiCD11c−MHCII− cells were initially gated, then further 
delineated by Ly6C and Ly6G expression to yield subsets with a 
Ly6ChiLy6G−, Ly6CloLy6G−, and Ly6C+Ly6G− phenotype as previ-
ously described in blood (Figure 1A). These myeloid subsets were 
then distinguishable on the basis of SSC, with the Ly6Chi subset 
as SSClo cells, Ly6Clo cells as SSChi and neutrophils as SSCmid 
(Figure 1A). Staining with antibodies specific for CD11b, CD11c, 
MHCII, Ly6C and Ly6G, and analysis of SSC can therefore be used 
to distinguish three main myeloid subsets in spleen, equivalent to 
those described previously in blood (7, 25).
The novel L-DC subset resembles myeloid DC in spleen on the 
basis of high CD11b expression. In order to further explore the 
relationship between L-DC and the three major myeloid subsets 
described above, T, B, and red blood cell-depleted splenocytes 
were gated as CD11bhiCD11cloMHCII− cells, and further tested 
for Ly6C and Ly6G expression. Since three distinct populations of 
cells were observed, Ly6C+Ly6G+ (19.9%), Ly6C+Ly6G− (27.1%), 
and Ly6C−Ly6G− (47.1%) (Figure  1B), these were selected for 
further study and termed “L-DC candidates.” FSC and SSC 
profiles distinguished Ly6C+Ly6G+ and Ly6C+Ly6G− candidates 
as FSChiSSCmid, while the Ly6C−Ly6G− subset was predominantly 
FSCloSSClo (Figure 1B). To fully delineate the L-DC subset and to 
distinguish it from myeloid cells, it was necessary to identify fur-
ther markers and to characterize all myeloid subsets concurrently.
Ly6Clo-resident monocytes in blood were previously 
distinguished from Ly6Chi-inflammatory monocytes on the 
basis of higher CD43 expression (10). In addition, eosinophils 
present in steady-state spleen were distinguishable from other 
myeloid cells through expression of Siglec-F (17, 19). Myeloid 
cells identified in Figure  1 were therefore stained for these 
markers. All CD11bhiCD11c− cells delineated by Ly6C and 
Ly6G expression expressed CD43 (Figure 2A). The majority of 
Ly6ChiLy6G− monocytes (~99%) and Ly6C+Ly6G+ neutrophils 
(~97%) did not express Siglec-F (Figure 2B). The Ly6CloLy6G− 
population contained a distinct CD43hi subset (83.7%), which 
corresponded to SSChiSiglec-F+ cells and therefore resembled 
AB
FigUre 1 | Phenotypic characterization of myeloid subsets in spleen. Spleen cells were depleted of T, B and red blood cells and stained with antibodies to 
CD11b, CD11c, MHCII, Ly6C, and Ly6G. Propidium iodide (PI, 1 μg/mL) staining was used to gate live (PI−) cells. (a) CD11bhiCD11c−MHCII− cells were initially gated 
on the basis of a blood monocyte phenotype. Further staining with Ly6C and Ly6G revealed three subpopulations with distinct FSC and SSC as reported in the 
literature (42). (B) L-DC were initially gated as CD11bhiCD11cloMHCII− cells. Further staining with Ly6C and Ly6G revealed three populations of “L-DC candidates” 
with overlapping FSC and SSC profiles: Ly6CloLy6G+, Ly6CloLy6G− and Ly6C−Ly6G−. Gating strategies were based on fluorescence minus one control, and numbers 
in gates represent % specific binding.
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eosinophils (Figures  2A,B). All L-DC candidates, irrespec-
tive of Ly6C/Ly6G delineation, expressed CD43 (Figure 2A). 
The Ly6CloLy6G− candidates displayed the largest CD43hi 
population (40.6%), also a reflection of resident monocytes. 
While the majority of cells in all subsets were Siglec-F−, each 
Ly6C−Ly6G−, Ly6C+Ly6G−, and Ly6C+Ly6G+ subset showed 
some low level contamination with Siglec-F+ eosinophils 
(Figure 2B).
The presence of Siglec-F+ cells among splenic myeloid cells 
therefore necessitated mapping out the eosinophil phenotype in 
relation to myeloid cells. As shown in Figure 2B, Ly6CloLy6G− 
myeloid cells contained a large subset of Siglec-F+ cells (79.3%), 
indicating a majority of eosinophils. The presence of eosinophils 
was also confirmed by transcriptome analysis, which revealed 
specific expression of CCR3 by this subset (unpublished data). 
In order to confirm the specificity of Siglec-F staining, a back-
gating strategy was applied to Siglec-F+ cells (Figure S1 in 
Supplementary Material). Siglec-F+ eosinophils were found 
to be mainly CD11bhiCD11c−Ly6CloLy6G−CD43+ cells. Since 
this phenotype also reflects Ly6Clo monocytes in blood, future 
stainings therefore involved Siglec-F gating to distinguish or 
exclude eosinophils from splenic subsets of interest.
The expression of macrophage-colony stimulating factor 
receptor (M-CSFR/CD115) has also proven useful to deline-
ate monocytes/macrophages and other myeloid subsets (43, 
44). Here, it was found that Ly6CloLy6G−Siglec-F+ eosinophils 
were CD115−, while Ly6ChiLy6G− monocytes were CD115+ 
(Figure  2C). Ly6C+Ly6G+ neutrophils were also CD115−, con-
sistent with reports in the literature (45). Among L-DC candi-
dates, 65% of the Ly6CloLy6G− subset, now thought to contain 
monocytes, expressed CD115. The Ly6C+Ly6G+ subset of L-DC 
candidates, thought to be contaminated with neutrophils and 
other undefined cells, showed 47% of cells as CD115+. However, 
the Ly6C−Ly6G− subset of L-DC candidates was clearly negative 
for CD115, distinguishing it from other CD11bhiCD11clo L-DC 
candidates (Figure 2C).
redefining splenic Myeloid subsets
Myeloid subsets in spleen were investigated further in terms 
of the expression of specific markers which are known to 
AB
C
D
FigUre 2 | Further delineation of myeloid cells on the basis of cD43, siglec-F, and cD115 expression. Spleen cells were prepared and stained as 
described in Figure 1 with the addition of antibodies specific for CD43, CD115, Siglec-F, and CX3CR1. Live (PI−) cells were gated as myeloid cells (CD11bhiCD11c−) 
and L-DC candidates (CD11bhiCD11clo). Myeloid cells were further divided to reveal Ly6ChiLy6G−, Ly6CloLy6G−, and Ly6CloLy6G+ subsets. L-DC were further 
delineated as three candidate subsets differing in Ly6C and Ly6G expression. Expression of (a) CD43, (B) Siglec-F, (c) CD115, and (D) CX3CR1 was determined 
on all subsets. Gates were set based on fluorescence minus one control, and numbers in gates represent % specific binding.
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distinguish myeloid cells. CX3CR1 expression has been associ-
ated with the differentiation of macrophages and DC from a 
macrophage/dendritic progenitor (MDP) (46–48), and Ly6Clo-
resident monocytes and Ly6Chi-inflammatory monocytes in 
blood have been described as CX3CR1hi and CX3CR1lo cells, 
respectively (3, 7). CX3CR1 transgenic mice tagged with green 
fluorescence protein (GFP) were therefore used to confirm that 
the subset of CD11bhiCD11c−Ly6CloLy6G−Siglec-F+ cells did 
not express CX3CR1 in line with the designation of eosinophils. 
When splenic SSChiLy6G− cells corresponding to CD11bhiCD1
1c−Ly6CloLy6G−Siglec-F+ cells were gated, very few cells were 
found to express CX3CR1 (6.78%; Figure 2D), consistent with 
their classification as eosinophils rather than monocytes. The 
gated CD11bhiCD11c−Ly6ChiLy6G− cells were found to be 
CX3CR1lo, so confirming their identity as Ly6Chi-inflammatory 
monocytes described by Geissmann et  al. (7) (Figure  2D). 
Finally, Ly6G+Ly6C+ cells were found to be CX3CR1− and so 
were likely to be neutrophils.
L-DC candidates were then analyzed for CX3CR1 expression. 
For this experiment, they were divided into three populations 
based on SSC and Ly6G staining, and Ly6C expression on candi-
date subsets gated on the basis of SSC and Ly6G was also verified 
by independent staining (data not shown). Of the three L-DC 
candidate subsets, SSChiLy6CloLy6G− cells were largely CX3CR1hi 
(63%), and along with their CD115 expression, reflected a 
phenotype consistent with Ly6Clo monocytes (Figure 2D). The 
Ly6C+Ly6G+ subset classified as neutrophils appeared hetero-
geneous with 43% CX3CR1hi cells. The SSCloLy6C−Ly6G− L-DC 
candidate, negative for CD115 expression, was also CX3CR1+. 
Low CX3CR1 expression was also observed on 48% of gated CD8− 
cDC and 23% of gated CD8+ cDC (Figure 2D), consistent with 
previous reports (49, 50). In terms of L-DC, the expression of 
CX3CR1 on SSCloLy6C−Ly6G− cells is consistent with a dendritic/
monocyte cell type.
l-Dc are Morphologically Distinct from 
Monocytes
In order to classify subsets further, myeloid and DC subsets were 
sorted to purity, prepared as cytospins, and visualized by Giemsa 
staining. Light microscopy was used to identify and quantitate 
cells based on morphology. Among CD11bhiCD11c− myeloid 
cells, the Ly6C+Ly6G+ subset (also 7/4+Siglec-F−) demonstrated 
characteristic neutrophil morphology, with a multi-lobate 
FigUre 4 | l-Dc development occurs independently of Batf-3 signaling. Splenocytes were harvested from B6.129S(C)-Batf3tm1.1Kmm (Batf-3−/−) and 
C57BL/6J (wild-type) mice and prepared as described in Figure 1. Cells were stained with two distinct antibody cocktails. The first included antibodies to CD11b, 
CD11c, Ly6C, Ly6G, MHC-II and CD8. The second contained antibodies to CD11b, CD11c, Ly6C, Ly6G, CD43 and Siglec-F. Prior to analysis, cells were stained 
with propidium iodide for gating live (PI−) cells. CD11bhiCD11c− myeloid cells were gated to give Ly6ChiLy6G−CD43+Siglec-F−-inflammatory monocytes (Infl mono), 
Ly6CloLy6G−CD43+Siglec-F+ eosinophils (Eos) and Ly6CloLy6G+CD43+Siglec-F− neutrophils (Neu). L-DC were gated as CD11bhiCD11cloLy6C−Ly6G−CD43+Siglec-F− 
cells, while CD11bhiCD11cloLy6CloLy6G−CD43hiSiglec-F− cells were gated as resident monocytes (Resi mono). CD8+cDC were gated as 
CD11b−CD11chiMHCII+CD8+Ly6C−Ly6G− cells, while CD8−cDC were gated as CD11b+CD11chiMHCII+CD8−Ly6C−Ly6G− cells. Subset size was estimated as % of 
the total DC and myeloid population in individual wild-type mice (WT) compared with Batf3−/− mice (KO). A bar is used to show mean values and p values are given. 
Statistically different subsets (p ≤ 0.05) are boxed.
FigUre 3 | Morphology of spleen dendritic and myeloid subsets. Splenocytes were sorted into myeloid subsets, L-DC candidates and cDC as described in 
Figure 2. Sorted subsets were cytospun on to slides and fixed prior to Giemsa staining. Photomicroscopy of subsets was performed at 600× magnification, bar 
10 μm. Italicized labels indicate revised subset classification based on identified morphology and cell surface phenotype. Ly6Chi and Ly6Clo monocytes are labeled 
as inflammatory and resident monocytes, respectively.
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nucleus and cytoplasm devoid of granules (Figure 3). Over two 
independent experiments, all cells counted from this subset 
showed similar neutrophil morphology (Table 1). Giemsa stain-
ing of sorted CD11bhiCD11c−Ly6ChiLy6G− (SiglecF−7/4−) cells 
revealed a bi-lobate nucleus and a cytoplasm devoid of granules 
(Figure 3). The majority of cells (>90%) displayed this morphol-
ogy (Table 1), confirming the phenotype of Ly6Chi-inflammatory 
monocytes. Gated CD11bhiCD11c−Ly6CloLy6G− (SiglecF+7/4−) 
TaBle 1 | Morphological characterization of spleen dendritic and myeloid subsets.
sorted subset subset  
classification
expta no. of 
cells
% cells with known morphologyb
eosinophil neutrophil Monocyte-like Dendritic-like
CD11bhiCD11c−Ly6ChiLy6G−CD43+Siglec-F− Inflammatory 
monocytes
I 72 1.4 – 97.2c 1.4
II 68 1.5 – 86.8 11.8
CD11bhiCD11c−Ly6CloLy6G−CD43hiSiglec-F+ Eosinophils I 72 100 – – –
II 72 100 – – –
CD11bhiCD11c−Ly6CloLy6G+CD43+Siglec-F− Neutrophils I 26 – 100 – –
II 18 – 100 – –
CD11bhiCD11cloLy6CloLy6G−CD43+/hiSiglec-F− Resident monocytes I 76 – – 68.4 31.6
II 80 – – 62.5 37.5
CD11bhiCD11cloLy6C−Ly6G−CD43+Siglec-F− L-DC I 78 10.3 – 42.3 47.4
II 84 6.0 – 32.1 62
CD11b−CD11chiLy6C−Ly6G−CD43−Siglec-F− CD8+ cDC I 41 – – 26.8 73.2
II 34 – – 17.7 82.4
CD11b+CD11chiLy6C−Ly6G−CD43−Siglec-F− CD8− cDC I 61 – – 13.1 86.9
II 59 1.7 – 15.3 83.1
aData are shown for two independent sorting experiments.
bCells were cytospun and stained with Giemsa for microscopic classification.
cDominant subsets are shown in bold.
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cells demonstrated multi-lobate nuclei with clear presence of 
orange granules in the cytoplasm, consistent with eosinophils and 
confirming a Siglec-F+ identity (Figure 2).
Among the CD8+ and CD8− cDC subsets, a majority (80–90%) 
of cells displayed the morphology of mononuclear dendritic-like 
cells with vacuoles evident in the cytoplasm and nuclei staining 
blue (Table 1; Figure 3). Among the CD11bhiCD11clo candidates, 
the Ly6C+Ly6G− subset revealed morphology resembling mono-
cytes with a bi-lobate nucleus and a cytoplasm devoid of granules 
(Figure 3). Combined with a SiglecF−CD43+/hiCX3CR1hiCD115+ 
phenotype, this population is reflective of Ly6Clo monocytes. A 
subpopulation of ~30% cells, however, was observed to show 
morphology more typical of DC (Table 1), and this could indicate 
an impure population. The Ly6C+Ly6G+ subset comprised mainly 
neutrophils, with ~10% monocytes (data not shown). Sorted 
Ly6C−Ly6G− L-DC were also heterogeneous, with the presence 
of both dendritic-like and monocyte-like cells. Across two experi-
ments, 47 and 62% of cells displayed a mononuclear dendritic-
like morphology with veiled membranes, short dendrites, and 
vacuoles evident in the cytoplasm, with 30–40% of cells showing 
more monocyte-like morphology (Table 1; Figure 3). Five to ten 
percent of cells represented eosinophils as a potential contami-
nant identified in Figure  2. Overall, Giemsa staining revealed 
the presence of a majority of dendritic-like cells in the CD11bh
iCD11cloLy6C−Ly6G− subset, and based on collective data, this 
subset most likely represents L-DC, with monocytes representing 
the major subpopulation of Ly6C+Ly6G− cells, and neutrophils 
comprising most of the Ly6C+Ly6G+ subset.
l-Dc are a Distinct lineage from cDc
While L-DC are phenotypically distinct from cDC, they show 
similarity in their endocytic and cross-presentation ability (36). 
To determine if L-DC and cDC derive from a common lineage 
progenitor, their prevalence was investigated in Batf3−/− mice. 
The expression Batf3 has been described for pre-cDC, with 
peak expression in differentiated CD8+ and CD8− cDC (51–53). 
Batf3−/− mice contain decreased numbers of CD8+ cDC, but not 
CD8− cDC, suggesting that Batf3 is essential in the development 
of CD8+ cDC from pre-cDC (51). Batf3 may co-operate with 
another factor to induce the final differentiation of CD8+ cDC, 
while CD8− cDC differentiation may occur independently of 
Batf3 (52).
The proportional representation of dendritic and other 
myeloid subsets in spleen relative to total splenic myeloid subsets 
of CD11b+ and/or CD11c+ cells was compared in mutant and 
wild-type mice. Subsets were delineated as described in Figure 3 
and Table 1. A significant drop in the number of CD8+ cDC was 
observed in Batf3−/− mice compared with wild-type mice consist-
ent with previous reports (Figure  5). However, the number of 
CD8− cDC in Batf3−/− varied with 4 of 10 Batf3−/− mice showing 
an increase in CD8− cDC, while another four showed lower 
numbers of CD8− cDC compared with controls. Variability in 
CD8− cDC numbers could suggest either multiple interactive 
effects leading to highly variable numbers, or heterogeneity 
among the CD8− cDC subset delineated here. The percentage 
of Ly6Chi-inflammatory monocytes also dropped significantly 
in Batf3−/− mice (Figure  4). L-DC, Ly6Clo-resident monocytes, 
and neutrophils displayed no change in percentage due to the 
Batf3 mutation. Eosinophils were the only cells that displayed an 
increase in percentage in Batf3−/− mice, but this could be consist-
ent with increased inflammation in these mice.
l-Dc Develop independently of FlT3l and 
gM-csF
Fms-like tyrosine kinase 3 (FLT3) signaling has been described 
as essential for cDC development in steady-state spleen (54). 
Administration of FLT3L during in vitro and in vivo cell devel-
opment leads to an increase in the number of splenic cDC and 
pDC (55–57). Similarly, knockdown of Flt3L leads to a two- to 
threefold drop in the number of splenic cDC and pDC in adult 
mice (54). In order to investigate whether L-DC development is 
also dependent on FLT3L, the percentage representation of cDC, 
AB
FigUre 5 | l-Dc development occurs independently of Flt3l and gM-csF. Splenocytes were harvested from C57BL/6J-Flt3Ltm1lmx (Flt3L−/−), C57BL/6J-
Csf2tm1Ard (GM-CSF−/−), and C57BL/6J (wild-type) mice, and prepared as described in Figure 1. Cells were stained with two distinct antibody cocktails and 
propidium iodide (PI) as described in Figure 4. Subset size was estimated as % of total DC and myeloid population in individual wild-type mice (WT) compared with 
(a) Flt3L−/− and (B) GM-CSF−/− mice (KO). A bar is used to show mean values and p values are given. Statistically different subsets (p ≤ 0.05) are boxed.
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L-DC and other myeloid subsets was analyzed relative to the 
total dendritic and myeloid cell population in adult Flt3L−/− and 
wild-type mice.
A sixfold reduction in proportion of CD11chi cells was 
observed in Flt3L−/− mice compared with wild-type mice, consist-
ent with the literature (58, 59) (data not shown). A significant 
~7-fold drop in percentage CD8− cDC among total dendritic 
and myeloid cells, and a significant drop in percentage of CD8+ 
cDC were observed in Flt3L−/− mice compared with wild-type 
mice (Figure 5A). There was also a significant drop in the per-
centage of Ly6Chi inflammatory and Ly6Clo-resident monocytes 
in Flt3L−/− mice (Figure  5A). In contrast, neither L-DC nor 
eosinophils were affected by absence of Flt3L expression dur-
ing development. Last, the percentage of neutrophils increased 
in Flt3L−/− mice (Figure  5A). These results predict a role for 
FLT3L in the development of cDC, and all monocytes, but not 
L-DC and eosinophils. The proportional increase in neutrophils 
could reflect inflammation in a mouse model which has reduced 
immune capacity.
During inflammation, Ly6Chi monocytes can give rise to 
mo-DC that produce TNF-α and inducible NO synthase. These 
have been called “Tip-DC” (7, 42, 60). Similarly, granulocyte-
macrophage colony-stimulating factor (GM-CSF) can induce 
formation of inflammatory type mo-DC after addition to cultures 
of bone marrow progenitors (34, 61, 62). In order to investigate 
a role for GM-CSF in the development of splenic dendritic and 
other myeloid subsets, changes in the populational representa-
tion of cDC, L-DC and myeloid subsets were investigated in 
GM-CSF−/− mice (Figure 5B). Previous studies have reported no 
change in the proportion of pDC and cDC in GM-CSF−/− mice (63, 
64). In this study, however, percentages of both CD8+ cDC and 
CD8− cDC were higher in GM-CSF−/− mice (Figure 5B), while 
percentages of both Ly6Chi and Ly6Clo were significantly lower 
(Figure 5B). The percentage of eosinophils in GM-CSF−/− mice 
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was significantly increased, while the percentage of neutrophils 
remained unaffected (Figure 5B). Proportional representation of 
L-DC was not significantly different, although more variable in 
GM-CSF−/− compared with wild type mice.
L-DC development therefore occurs independently of both 
FLT3L and GM-CSF, while the development of monocyte sub-
sets is clearly dependent on both factors (Figure 5). While cDC 
subsets are dependent on FLT3L for development, they develop 
independently of GM-CSF. In fact, in the absence of GM-CSF, 
there appears to be a compensatory increase in the development 
of cDC as well as eosinophils (Figure 5). These results distinguish 
L-DC from both cDC and other myeloid subsets, since L-DC 
develop independently of BATF3, FLT3L and GM-CSF.
DiscUssiOn
In addressing the issue of myeloid cell subset classification in 
spleen, a recent paper suggested a unified nomenclature for DC, 
monocytes, and macrophages based primarily on ontogeny, 
and secondly by location, function, and phenotype (65). The 
delineation of splenic Ly6Clo monocytes was made on the basis 
of the described phenotype and function of previously described 
resident monocytes in blood (7, 25). Now, it is shown here that 
the spleen contains distinct populations of Ly6ChiCD11c− and 
Ly6CloCD11clo monocytes, as well Ly6CloCD11c− eosinophils. 
The latter population appears to be present in higher number in 
spleen and so more likely to obscure the Ly6CloCD11clo monocyte 
population in the absence of staining for CD11c and the SiglecF 
marker specific for eosinophils.
In order to better define an in  vivo equivalent L-DC 
population in relation to splenic myeloid subsets, it was 
necessary to analyze dendritic and other myeloid subsets 
concurrently. Since blood monocytes are the most widely 
characterized monocytes, their phenotype was used as the 
starting point for analysis of splenic monocytes (19, 47). Ly6Clo 
and Ly6Chi monocytes in blood were previously described as 
CD11bhiCD11c−MHCII−Ly6G− cells (3, 6, 7, 10, 11). Siglec-F, 
an inhibitory receptor expressed by murine eosinophils (66, 
67) proved definitive for analysis of eosinophils in this subset 
(Figure  2). The CD11bhiCD11c−MHCII−Ly6C+Ly6G− subset 
of cells in spleen was found to comprise a majority (87%) of 
Siglec-F+ eosinophils (Figure 2), with Ly6Chi monocytes clearly 
Siglec-F− (Figure 2). The results of this study now confirm the 
definition of splenic Ly6Clo monocytes as CD11clo cells (9, 10, 
68) lying within the Ly6C+Ly6G− population.
To further test these initial predictions, the myeloid markers 
CX3CR1 and CD115 were employed. CX3CR1 is a known marker 
of Ly6Clo-resident monocytes (7, 25), and CD115 is a marker 
of bone marrow-derived myeloid cells (43, 44). High levels of 
CX3CR1 were shown to be expressed by CD11clo cells that were 
also Ly6CloLy6G−, so confirming their similarity with resident 
monocytes (Figure 2D). In addition, these cells also expressed 
CD115 (Figure  2C). Since CD115 was not expressed by the 
putative L-DC subset, this suggests different lineage origins for 
L-DC and Ly6Clo monocytes. In line with the literature, Ly6Chi 
monocytes are CD115+, while both neutrophils and eosinophils 
lacked CD115 expression (Figure 2C).
Phenotypic studies were informative although not definitive 
in the identification of L-DC in relation to other myeloid subsets. 
Morphological characterization by May-Grünwald-Giemsa 
staining was used to confirm predicted subsets. Blood monocytes 
have a bi-lobate nucleus and minimal cytoplasm devoid of gran-
ules (Figure 4) (7, 10). Ly6Chi monocytes in spleen displayed this 
morphology in line with their blood cell counterparts (Figure 4) 
(16, 19). Giemsa staining also confirmed that the splenic subset 
defined here as eosinophils had a characteristic multi-lobate 
nucleus with orange granules in the cytoplasm, consistent with 
their phenotypic classification as Siglec-F+ eosinophils (Figure 4) 
(69). The identified Ly6Clo monocyte subset identified as CD11clo 
cells displayed morphology consistent with blood monocytes 
and not DC. These cells had a bi-lobate nucleus with minimal 
cytoplasm which lacked granules (Figure 3). Therefore morpho-
logical studies supported phenotypic studies, showing that spleen 
resident Ly6Clo monocytes lie within the CD11bhiCD11cloLy6C+
Ly6G− population. Morphological analysis also showed that all 
Ly6G+ subsets comprised a majority of neutrophils with charac-
teristic multi-lobate nucleus (Figure 4). This was also confirmed 
by their 7/4 staining (data not shown).
The morphology of splenic DC is known to be to be quite 
distinct from the first described DC subset of Langerhans cells, 
which have long membrane projections (70, 71). Here, CD8+ 
cDC were shown to reflect a majority of mononuclear cells with 
vacuoles evident in the cytoplasm. Similarly, CD8− cDC and up to 
60% of the Ly6C−Ly6G− L-DC subset also demonstrated similar 
cDC morphology with cytoplasmic vacuoles (Figure  3). These 
cells also showed veiled membranes with a few small dendrities, 
although this cannot be clearly be distinguished on cytospun 
cells. Combined phenotypic and morphological studies therefore 
identify L-DC as a subset of CD11bhiCD11cloLy6C−Ly6G− cells, 
with the majority demonstrating the morphology of a DC. A 
combination of studies shown here, therefore identify L-DC 
as a distinct cell type, reflecting the in  vivo equivalent of cells 
produced in longterm cultures of spleen, LTC-DC. While it has 
been possible to phenotypically and morphologically identify an 
in vivo counterpart of the in vitro-produced L-DC, classification 
of this cell type as dendritic will be dependent on demonstration 
of their ability to activate naïve T cells and to cross present antigen 
as shown previously for in vitro produced cells (31, 33).
Knockout mice studies have played a definitive role in 
identifying genes essential for development. Since none of the 
mutant mice studied here are embryonically lethal, and none 
of the genes mutated are crucial for survival, it was possible to 
obtain essential information about the development of L-DC in 
relation to other splenic myeloid subsets. CD11bhiCD11cloLy6C−
Ly6G− L-DC development occurs independently of factors that 
regulate cDC and monocyte development, including BATF3, 
FLT3L, and GM-CSF. These findings distinguish L-DC from cDC 
as a separate lineage of cells, and identify them as distinct from 
splenic monocyte and granulocyte subsets.
Previously, this lab published evidence that L-DC can arise 
in vitro from self-renewing bone marrow-derived hematopoietic 
stem cells (HSC) and multipotential progenitors (MPP) follow-
ing co-culture over splenic stromal lines (72, 73). These findings 
confirm that L-DC arise from a progenitor distinct from the CDP 
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also present in bone marrow (74). The production of L-DC was 
unaffected in Batf-3−/− mice, suggesting that L-DC develop as a 
distinct lineage separated from cDC. In Batf-3−/− mice, a signifi-
cant drop in the percentage of inflammatory monocytes was also 
observed. Recent studies in Batf-3−/− mice also showed a defect in 
the differentiation of CD4 T helper cells into T helper 17 (Th17) 
cells (75, 76) essential for supporting inflammatory responses 
involving pathogens or autoimmunity (77, 78). It is interesting to 
speculate that Ly6Chi monocytes may be important mediators of 
Th17 cell development from CD4+ T helper cells.
The binding of FLT3L to FLT3 triggers the development of 
cDC from pre-cDC (34, 63, 79), and the knockout of either Flt3 
or Flt3L adversely affects cDC development (63, 79). In this study, 
a significant drop in the production of splenic CD8+ cDC and 
CD8− cDC was observed in Flt3L−/− mice (34, 63). FLT3 is also a 
marker of common lymphoid progenitors (CLP) and CMP (59), 
such that the delivery of additional FLT3L to mice can lead to 
an expansion of the monocyte pool along with cDC (58, 59). 
Expression of the FLT3 receptor on myeloid precursors, and the 
development of monocytes following FLT3L stimulation sug-
gests that FLT3 receptor tyrosine kinase signaling plays a role in 
monocyte development. In agreement with this, Waskow et  al. 
(79) showed an increase in the numbers of MDP which give rise 
to CDP and monocytes following FLT3L stimulation in vivo and 
in vitro. A reduction in the number of Ly6Clo resident and Ly6Chi-
inflammatory monocytes in Flt3L−/− mice shown here also sup-
ports a role for FLT3 signaling in monocyte development. Since 
L-DC development is not compromised in Flt3L−/− mice, L-DC 
are distinguishable in terms of development and lineage origin 
from both cDC subsets, and from the major monocyte subsets 
in spleen.
Both FLT3L and GM-CSF have been used for in vitro expan-
sion of DC. Previously, it was shown that the culture of bone 
marrow precursors with FLT3L-generated cDC and pDC, while 
GM-CSF in the same system, generated inflammatory mo-DC 
(61, 63). GM-CSF−/− mice were employed here to determine any 
role for GM-CSF in the in vivo development of L-DC. Deficiency 
in GM-CSF production did not affect the development of L-DC, 
suggesting that L-DC are not likely to be an inflammatory type 
cell dependent on GM-CSF signaling for development from 
myeloid precursors. By comparison, in GM-CSF−/− mice, the 
percentage of the two main monocyte subsets was reduced, 
consistent with their development in response to GM-CSF and 
probably inflammation. The percentage of Ly6Chi-inflammatory 
monocytes was fourfold lower in GM-CSF−/− mice, while Ly6Clo-
resident monocytes showed a smaller but significant 1.4-fold 
reduction. Previous studies in GM-CSF−/− mice showed no 
significant change in peripheral blood myeloid subsets, although 
alveolar macrophages were found to be defective (80). However, 
that study did not investigate splenic myeloid subsets to the level 
of phenotypic detail used here. Under steady-state conditions, 
the development of cDC occurs independently of GM-CSF (63). 
In this study, the percentage of CD8+ cDC and CD8− cDC was 
found to be significantly increased in GM-CSF−/− mice, although 
an increase in cDC numbers could occur as a compensatory 
change in spleen due to reduction in the number of monocytes. 
This study also showed that eosinophils increased in number in 
spleens of GM-CSF−/− mice, suggesting that the development of 
eosinophils occurs independently of GM-CSF. An increase in 
eosinophil number could also reflect an inflammatory or allergic 
state in GM-CSF−/− mice.
In conclusion, a novel dendritic-like cell type termed L-DC 
has been defined among multiple spleen myeloid subsets as 
CD11bhiCD11cloMHCII−CD43loCD115−Siglec-F−CX3CR1loLy6
C−Ly6G− cells, resembling in vitro grown LTC-DC (32, 33). In 
defining L-DC, populations of monocytes and granulocytes were 
also closely considered. Another outcome has therefore been 
the definition of eosinophils in spleen as CD11bhiCD11c−Ly6C
+Ly6G−Siglec-F+ cells. Ly6Clo-resident monocytes in spleen have 
now been identified more completely as CD11bhiCD11cloLy6C+
Ly6G−CD43+CX3CR1hiCD115+Siglec-F− cells. A study of subset 
prevalence in knockout mouse models confirmed the definition 
of L-DC in terms of their distinct lineage origin, establishing that 
L-DC develop independently of Batf3 expression essential for 
cDC development, and also independent of the FLT3L/GM-CSF 
growth factors necessary for cDC and monocyte development in 
spleen.
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